

DAFTAR PUSTAKA

- Ahmed, M., 2012. Isoniazid-Associated Uric Acid Retention in the Lizard, *Uromastix hardwickii* 3.
- Aibana, O., Bachmaha, M., Krasiuk, V., Rybak, N., Flanigan, T.P., Petrenko, V., dkk., 2017. Risk factors for poor multidrug-resistant tuberculosis treatment outcomes in Kyiv Oblast, Ukraine. *BMC infectious diseases*, **17**: 129.
- Akshata, J.S., Swapna, R., Chakraborty, A., Somashekar, M., dan Buggi, S., 2015. Hypothyroidism in MDR-TB treatment – Rare occurrence but a major concern. *Egyptian Journal of Chest Diseases and Tuberculosis*, **64**: 671–674.
- Aminy, R.Z. dan Mardiana, N., 2020. Bartter-like Syndrome In a Patient Receiving Capreomycin For The Treatment Of Multidrug-Resistant Tuberculosis. *Current Internal Medicine Research and Practice Surabaya Journal*, **1**: 44.
- Anderson, L.F., Tamne, S., Watson, J.P., Cohen, T., Mitnick, C., Brown, T., dkk., 2013. Treatment outcome of multi-drug resistant tuberculosis in the United Kingdom: retrospective-prospective cohort study from 2004 to 2007. *Euro Surveillance: Bulletin Europeen Sur Les Maladies Transmissibles = European Communicable Disease Bulletin*, **18**: 20601.
- Ardhianto, D., Suharjono, Soedarsono, dan Fatmawati, U., 2021. Analysis of the side effect of QTc interval prolongation in the bedaquiline regimen in drug resistant tuberculosis patients. *Journal of Basic and Clinical Physiology and Pharmacology*, **32**: 421–427.
- Arroyo, L.Á., Gil, M.P., Grana, E.C., dan Baines, J.P.O., 2007. Trombocitopenia grave inducida por levofloxacin. *Farmacia Hospitalaria*, **31**: 2.
- Auclair, B., Nix, D.E., Adam, R.D., James, G.T., dan Peloquin, C.A., 2001. Pharmacokinetics of Ethionamide Administered under Fasting Conditions or with Orange Juice, Food, or Antacids. *Antimicrobial Agents and Chemotherapy*, **45**: 810–814.
- Azhar, W., Zaidi, F., dan Hannan, A., 2020. Isoniazid Induced Pure Red Blood Cell Aplasia. *Cureus*, .
- Badrinath, M. dan John, S., 2022. Isoniazid Toxicity, dalam: *StatPearls*. StatPearls Publishing, Treasure Island (FL).
- Bailey, S.L. dan Grant, P., 2011. ‘The tubercular diabetic’: the impact of diabetes mellitus on tuberculosis and its threat to global tuberculosis control. *Clinical Medicine*, **11**: 344–347.
- Banerjee, S. dan Banerjee, M., 2005. Diabetes and tuberculosis interface. *Journal of the Indian Medical Association*, **103**: 318, 320, 322 passim.
- Bashour, H. dan Mamaree, F., 2003. *Gender differences and tuberculosis in the Syrian Arab Republic: patients’ attitudes, compliance and outcomes*. *EMHJ*, **9**: 757–768.
- Begum, V., de Colombani, P., Das Gupta, S., Salim Md. A., H., Hussain, H., Pietroni, M., dkk., 2001. *Tuberculosis and patient gender in Bangladesh: sex differences in diagnosis and treatment outcome*. *IJTLD*, **5**: 604–610.

- Behera, C., Krishna, K., dan Singh, H.R., 2014. Antitubercular drug-induced violent suicide of a hospitalised patient. *Case Reports*, **2014**: bcr2013201469–bcr2013201469.
- Bethesda, 2012. *Bedaquiline*, dalam: LiverTox: Clinical and Research Information on Drug-Induced Liver Injury. National Institute of Diabetes and Digestive and Kidney Diseases, Bethesda (MD).
- Biranu, E., Wolde, M., Negesso, A.E., Hailu Tola, H., dan Molla Sisay, M., 2021. Thyroid Profile and Factors Associated with Hypothyroidism Among Multidrug-Resistant Tuberculosis Patients Attending Saint Peter's Specialized Hospital Addis Ababa, Ethiopia. *Infection and Drug Resistance*, **Volume 14**: 2675–2684.
- Bird, S.T., Etminan, M., Brophy, J.M., Hartzema, A.G., dan Delaney, J.A.C., 2013. Risk of acute kidney injury associated with the use of fluoroquinolones. *Canadian Medical Association Journal*, **185**: E475–E482.
- Bishop, E., Melvani, S., Howden, B.P., Charles, P.G.P., dan Grayson, M.L., 2006. Good Clinical Outcomes but High Rates of Adverse Reactions during Linezolid Therapy for Serious Infections: a Proposed Protocol for Monitoring Therapy in Complex Patients. *Antimicrobial Agents and Chemotherapy*, **50**: 1599–1602.
- Bolhuis, M.S., Tiberi, S., Sotgiu, G., Lorenzo, S.D., Kosterink, J.G.W., Werf, T.S. van der, dkk., 2015. Linezolid tolerability in multidrug-resistant tuberculosis: a retrospective study. *European Respiratory Journal*, **46**: 1205–1207.
- Borisov, S.E., Dheda, K., Enwerem, M., Romero Leyet, R., D'Ambrosio, L., Centis, R., dkk., 2017. Effectiveness and safety of bedaquiline-containing regimens in the treatment of MDR- and XDR-TB: a multicentre study. *European Respiratory Journal*, **49**: 1700387.
- Boyles, T.H., Hughes, J., Cox, V., Burton, R., Meintjes, G., dan Mendelson, M., 2014. False-positive Xpert® MTB/RIF assays in previously treated patients: need for caution in interpreting results. *The International Journal of Tuberculosis and Lung Disease*, **18**: 876–878.
- BPOM RI, 2015. 'Cek Produk BPOM - BPOM RI', . URL: <https://cekbpom.pom.go.id/home/produk/43697j6btnj7i7m6p0e1lmdrt0/al1/row/10/page/1/order/4/DESC/search/5/bedaquiline> (diakses tanggal 19/9/2021).
- BPOM RI, 2020. *Modul Farmakovigilans Bagi Tenaga Profesional Kesehatan*.
- Brewer, L. dan Williams, D., 2012. *Drug Interactions that Matter*. Medicine, Clinical Pharmacology **40**: 371–375.
- Buziashvili, M., Mirtskhulava, V., Kipiani, M., Blumberg, H.M., Baliashvili, D., Magee, M.J., dkk., 2019. Rates and risk factors for nephrotoxicity and ototoxicity among tuberculosis patients in Tbilisi, Georgia. *The International Journal of Tuberculosis and Lung Disease*, **23**: 1005–1011.
- Cameron, L.H. dan Starke, J.R., 2020. *Tuberculosis (Mycobacterium tuberculosis)*, dalam: Nelson Textbook of Pediatrics. Elsevier, hal. 1565–1582.

- Centers for Disease Control and Prevention, 2013. *Provisional CDC Guidelines for the Use and Safety Monitoring of Bedaquiline Fumarate (Sirturo) for the Treatment of Multidrug-Resistant Tuberculosis*. MMWR, **62**: 8.
- Chem, E.D., Van Hout, M.C., dan Hope, V., 2019. *Treatment outcomes and antiretroviral uptake in multidrug-resistant tuberculosis and HIV co-infected patients in Sub Saharan Africa: a systematic review and meta-analysis*. BMC Infectious Diseases, **19**: 723.
- Chiang, S.S. dan Starke, J.R., 2018. *Mycobacterium tuberculosis*, dalam: Principles and Practice of Pediatric Infectious Diseases. Elsevier, hal. 790–806.
- Cholo, M.C., Steel, H.C., Fourie, P.B., Germishuizen, W.A., dan Anderson, R., 2012. Clofazimine: current status and future prospects. *Journal of Antimicrobial Chemotherapy*, **67**: 290–298.
- Chumakova, E., Abdullaev, R., dan Komissarova, O., 2020a. Hyperuricemia in patients with newly detected MDR tuberculosis. *European Respiratory Journal*, **56**: .
- Chumakova, E., Abdullaev, R., dan Komissarova, O., 2020b. Hyperuricemia in patients with newly detected MDR tuberculosis. *European Respiratory Journal*, **56**: .
- Court, R., Centner, C.M., Chirehwa, M., Wiesner, L., Denti, P., de Vries, N., dkk., 2021a. Neuropsychiatric toxicity and cycloserine concentrations during treatment for multidrug-resistant tuberculosis. *International Journal of Infectious Diseases*, **105**: 688–694.
- Court, R., Centner, C.M., Chirehwa, M., Wiesner, L., Denti, P., de Vries, N., dkk., 2021b. Neuropsychiatric toxicity and cycloserine concentrations during treatment for multidrug-resistant tuberculosis. *International Journal of Infectious Diseases*, **105**: 688–694.
- Cox, E. dan Laessig, K., 2014. *FDA Approval of Bedaquiline — The Benefit–Risk Balance for Drug-Resistant Tuberculosis*. NEJM, **371**: 689–691.
- Cunha, J.P., 2022. 'Side Effects of Paser (Aminosalicylic Acid), Warnings, Uses', *RxList*. URL: <https://www.rxlist.com/paser-side-effects-drug-center.htm> (diakses tanggal 20/10/2022).
- Darmayani, I.G.A.A.P.S., Ascobat, P., Instiaty, Sugiri, Y.J.R., dan Sawitri, N., 2022. Bedaquiline Effect on QT Interval of Drugs-Resistant Tuberculosis Patients: Real World Data. *Acta Med Indones-Indones J Intern Med*, **54**: 389–396.
- Di Gennaro, F., Vittozzi, P., Gualano, G., Musso, M., Mosti, S., Mencarini, P., dkk., 2020. *Active Pulmonary Tuberculosis in Elderly Patients: A 2016–2019 Retrospective Analysis from an Italian Referral Hospital*. Antibiotics, **9**: 489.
- Diallo, A., Diallo, B.D., Camara, L.M., Kounoudji, L.A.N., Bah, B., N'Zabintawali, F., dkk., 2020. Different profiles of body mass index variation among patients with multidrug-resistant tuberculosis: a retrospective cohort study. *BMC Infectious Diseases*, **20**: 315.
- Dinkes Provinsi Jawa Tengah, 2020. *Buku Saku Kesehatan Tahun 2019*. Dinkes Provinsi Jawa Tengah, Semarang.

- Direktorat Jenderal Pencegahan dan Pengendalian Penyakit, 2020a. *Petunjuk Teknis Pendampingan Pasien Tuberkulosis Resistan Obat Oleh Komunitas*. Kementerian Kesehatan RI, Jakarta.
- Direktorat Jenderal Pencegahan dan Pengendalian Penyakit, 2020b. *Petunjuk Teknis Penatalaksanaan Tuberkulosis Resistan Obat di Indonesia*. Kementerian Kesehatan RI, Jakarta.
- Direktorat Jenderal Pencegahan dan Pengendalian Penyakit, 2021. *Surat Edaran Kementerian Kesehatan RI Tentang Perubahan Alur Diagnosis Dan Pengobatan Tuberkulosis Di Indonesia*. Kementerian Kesehatan RI.
- Dooley, K.E., Rosenkranz, S.L., Conradie, F., Moran, L., Hafner, R., von Groote-Bidlingmaier, F., dkk., 2021. QT effects of bedaquiline, delamanid, or both in patients with rifampicin-resistant tuberculosis: a phase 2, open-label, randomised, controlled trial. *The Lancet Infectious Diseases*, **21**: 975–983.
- drugs.com, 2022a. 'Drug Interaction Report: bedaquiline, clofazimine', *Drugs.com*. URL: https://www.drugs.com/interactions-check.php?drug_list=3439-0,699-0 (diakses tanggal 10/9/2022).
- drugs.com, 2022b. 'Drug Interaction Report: bedaquiline, ethambutol, pyrazinamide, isoniazid, ethionamide, Paser', *Drugs.com*. URL: https://www.drugs.com/interactions-check.php?drug_list=1033-0,1048-0,1393-0,166-70,1970-0,3439-0 (diakses tanggal 10/9/2022).
- Elmi, O.S., Hasan, H., Abdullah, S., Mat Jeab, M.Z., Ba, Z., dan Naing, N.N., 2016. *Treatment Outcomes of Patients with Multidrug-Resistant Tuberculosis (MDR- TB) Compared with Non-MDR-TB Infections in Peninsular Malaysia*. *MJMS*, **23**: 17–25.
- Farley, J.E., Ram, M., Pan, W., Waldman, S., Cassell, G.H., Chaisson, R.E., dkk., 2011. Outcomes of multi-drug resistant tuberculosis (MDR-TB) among a cohort of South African patients with high HIV prevalence. *PloS One*, **6**: e20436.
- Fisher-Hoch, S., Whitney, E., McCormick, J., Crespo, G., Smith, B., Rahbar, M., dkk., 2009. Type 2 diabetes and multidrug-resistant tuberculosis. *Scandinavian Journal of Infectious Diseases*, **40**: 888–893.
- Fitzgerald, D.W., Sterling, T.R., dan Haas, D.W., 2020. *Mycobacterium tuberculosis*, dalam: Mandell, Douglas, and Bennett's Principles and Practice of Infectious Diseases. Elsevier Inc, hal. 2985–3021.
- Fox, G.J. dan Menzies, D., 2013. *A Review of the Evidence for Using Bedaquiline (TMC207) to Treat Multi-Drug Resistant Tuberculosis*. *Infectious Diseases and Therapy*, **2**: 123–144.
- Gadallah, M.A., Mokhtar, A., Rady, M., El-Moghazy, E., Fawzy, M., dan Kandil, S.K., 2016. *Prognostic factors of treatment among patients with multidrug-resistant tuberculosis in Egypt*. *JFMA*, **115**: 997–1003.
- Ganiger, A., Patil, L., dan Mrudula, N., 2019. Evaluation of Serum Electrolyte Status among Normal Healthy Individuals and Newly Diagnosed Cases of Pulmonary TB in Tertiary Care Hospital in Bidar: An Observational Study. *Indian Journal of Medical Biochemistry*, **23**: 316–319.

- Gao, J.-T., 2021. *Bedaquiline-containing regimens in patients with pulmonary multidrug-resistant tuberculosis in China: focus on the safety 10*.
- Ghori, S.S., Quddus, M.A., dan Khalid, H., 2017. A Clinical Study of Acute Kidney Injury on using Antituberculosis Drugs in Geriatrics. *Research Journal of Pharmacy and Technology*, **10**: 1746–1750.
- Guglielmetti, L., Tiberi, S., Burman, M., Kunst, H., Wejse, C., Togonidze, T., dkk., 2018. QT prolongation and cardiac toxicity of new tuberculosis drugs in Europe: a Tuberculosis Network European Trialsgroup (TBnet) study. *European Respiratory Journal*, **52**: 1800537.
- Habibi, M.R., Bakhtiar, A., Indiatuti, D.N., dan Meliana, R.Y., 2022. Diabetes Mellitus and History of Tuberculosis Treatment as Risk Factors of Developing Multidrug-Resistant Tuberculosis at TB Polyclinic Dr. Soetomo General Hospital 2019 - 2020. *Jurnal Ilmiah Universitas Batanghari Jambi*, **22**: 537.
- Hartshorn, E.A. dan Tatro, D.S., 2015. *Principles of Drug Interactions*, dalam: Drug Interaction Facts 2015: The Authority on Drug Interactions. Wolters Kluwer Health, St. Louis, Missouri, hal. xvii.
- Hewison, C., Khan, U., Bastard, M., Lachenal, N., Coutisson, S., Osso, E., dkk., 2022. Safety of Treatment Regimens Containing Bedaquiline and Delamanid in the endTB Cohort. *Clinical Infectious Diseases*, **75**: 1006–1013.
- Heysell, S.K., Ahmed, S., Rahman, Md.T., Akhanda, Md.W., Gleason, A.T., Ebers, A., dkk., 2018a. Hearing loss with kanamycin treatment for multidrug-resistant tuberculosis in Bangladesh. *European Respiratory Journal*, **51**: 1701778.
- Heysell, S.K., Ahmed, S., Rahman, Md.T., Akhanda, Md.W., Gleason, A.T., Ebers, A., dkk., 2018b. Hearing loss with kanamycin treatment for multidrug-resistant tuberculosis in Bangladesh. *European Respiratory Journal*, **51**: 1701778.
- Ibrahim, L.M., Hadejia, I.S., Nguku, P., Dankoli, R., Waziri, N.E., Akhimien, M.O., dkk., 2014. Factors associated with interruption of treatment among Pulmonary Tuberculosis patients in Plateau State, Nigeria. 2011. *The Pan African Medical Journal*, **17**: 78.
- Ignatius, E.H. dan Dooley, K.E., 2019. *New Drugs for the Treatment of Tuberculosis*. Clinics in Chest Medicine, **40**: 811–827.
- Isaakidis, P., Casas, E.C., Das, M., Tseretopoulou, X., Ntzani, E.E., dan Ford, N., 2015. *Treatment outcomes for HIV and MDR-TB co-infected adults and children: systematic review and meta-analysis*. IJTLD, **19**: 969–978.
- Isralls, S., Baisley, K., Ngam, E., Grant, A.D., dan Millard, J., 2021. QT Interval Prolongation in People Treated With Bedaquiline for Drug-Resistant Tuberculosis Under Programmatic Conditions: A Retrospective Cohort Study. *Open Forum Infectious Diseases*, **8**: ofab413.
- Ja, J., 2000. Predictability of the effects of race or ethnicity on pharmacokinetics of drugs. *International journal of clinical pharmacology and therapeutics*, **38**: .

- Jamaluddin, Nizamuddin, Shah, A., dan Iqbal, W., 2018. Hyperuricemia in Patients Taking Anti-Tuberculosis Drugs Including Pyrazinamide for both Category-1 and Category-2 Tuberculosis, in Population of KPK-Pakistan. *Med. Forum*, **29**: 5.
- Jan, F., Hasan, M., Muhamad, N., Wali, S., Akbar, H.S., Atta, Q.M., dkk., 2017. Electrolytes imbalance caused by amikacin in patients receiving multi drug resistance- tuberculosis treatment at Hazara region Kpk, Pakistan. *Tuberkuloz ve Toraks*, **65**: 193–201.
- John, F., Oluronbi, R., dan Pitchumoni, C.S., 2016. Levofloxacin-induced rhabdomyolysis: a case report. *Journal of Medical Case Reports*, **10**: 235.
- Kandasamy, A. dan Srinath, D., 2012. Levofloxacin-induced acute anxiety and insomnia. *Journal of Neurosciences in Rural Practice*, **3**: 212–214.
- Kardalas, E., Paschou, S.A., Anagnostis, P., Muscogiuri, G., Siasos, G., dan Vryonidou, A., 2018. Hypokalemia: a clinical update. *Endocrine Connections*, **7**: R135–R146.
- Karim, F., Ahmed, F., Begum, I., Johansson, E., dan Diwan, V.K., 2008. *Female-male differences at various clinical steps of tuberculosis management in rural Bangladesh [Short communication]*. *IJTLD*, **12**: 1336–1339.
- Katrak, S., Lowenthal, P., Shen, R., True, L., Henry, L., dan Barry, P., 2021. Bedaquiline for multidrug-resistant tuberculosis and QTc prolongation in California. *Journal of Clinical Tuberculosis and Other Mycobacterial Diseases*, **23**: 100216.
- Kazi, S. dan Preston, G., 2018. Drug Induced Thrombotic Microangiopathy Caused by Levofloxacin. *Journal of the Royal College of Physicians of Edinburgh*, **48**: 127–129.
- Kementerian Kesehatan RI, 2016. *Peraturan Menteri Kesehatan Republik Indonesia No. 67 Tahun 2016 Tentang Penanggulangan Tuberkulosis*. Kemenkes RI, Jakarta.
- Kementerian Kesehatan RI, 2020. *Juknis Penatalaksanaan Tuberkulosis Resistan Obat di Indonesia*. Kemenkes RI, Jakarta.
- Kempker, R.R., Barth, A.B., Vashakidze, S., Nikolaishvili, K., Sabulua, I., Tukvadze, N., dkk., 2015. *Cavitary Penetration of Levofloxacin among Patients with Multidrug-Resistant Tuberculosis*. *Antimicrobial Agents and Chemotherapy*
- Kervezee, L., Gotta, V., Stevens, J., Birkhoff, W., Kamerling, I., Danhof, M., dkk., 2016. Levofloxacin-Induced QTc Prolongation Depends on the Time of Drug Administration. *CPT: Pharmacometrics & Systems Pharmacology*, **5**: 466–474.
- Khan, F.A., Salim, M.A.H., Cros, P. du, Casas, E.C., Khamraev, A., Sikhondze, W., dkk., 2017. Effectiveness and safety of standardised shorter regimens for multidrug-resistant tuberculosis: individual patient data and aggregate data meta-analyses. *European Respiratory Journal*, **50**: .
- Khan, S., Andries, A., Pherwani, A., Saranchuk, P., dan Isaakidis, P., 2014. Patch-testing for the management of hypersensitivity reactions to second-line anti-tuberculosis drugs: a case report. *BMC Research Notes*, **7**: 537.

- Kim, J., Kwak, N., Lee, H.Y., Kim, T.S., Kim, C.-K., Han, S.K., dkk., 2016. *Effect of drug resistance on negative conversion of sputum culture in patients with pulmonary tuberculosis*. *IJID*, **42**: 64–68.
- Kondoy, P.P.H., Rombot, D.V., Palandeng, H.M.F., dan Pakasi, T.A., 2014. Faktor-Faktor Yang Berhubungan Dengan Kepatuhan Berobat Pasien Tuberkulosis Paru di Lima Puskesmas di Kota Manado. *JURNAL KEDOKTERAN KOMUNITAS DAN TROPIK*, **2**: .
- Kuchukhidze, G., Kumar, A.M.V., de Colombani, P., Khogali, M., Nanava, U., Blumberg, H.M., dkk., 2014. Risk factors associated with loss to follow-up among multidrug-resistant tuberculosis patients in Georgia. *Public Health Action*, **4**: S41–S46.
- Kumar, R., Khan, S., Sen, P., dan Banerjee, S., 2020. A Study to Detect Liver Enzyme Dysfunction among Patients on First Line Anti-Tubercular Drugs from RNTCP during the Course of Anti-TB Treatment. *Journal of Evolution of Medical and Dental Sciences*, **9**: 645–650.
- Kurniawati, F., Sulaiman, S.A.S., dan Gillani, S.W., 2012. Study On Drug-Resistant Tuberculosis And Tuberculosis Treatment On Patients With Drug Resistant Tuberculosis In Chest Clinic Outpatient Department **4**: 5.
- Lan, Zhiyi, Ahmad, Nafees, Baghaei, Parvaneh, Barkane, Linda, Benedetti, Andrea, Brode, S.K., dkk., 2020. Drug-associated adverse events in the treatment of multidrug-resistant tuberculosis: an individual patient data meta-analysis. *The Lancet Respiratory Medicine*, **8**: 383–394.
- Lange, C., Abubakar, I., Alffenaar, J.-W.C., Bothamley, G., Caminero, J.A., Carvalho, A.C.C., dkk., 2014. Management of patients with multidrug-resistant/extensively drug-resistant tuberculosis in Europe: a TBNET consensus statement. *European Respiratory Journal*, **44**: 23–63.
- Lawrence Flick Memorial Tuberculosis Clinic, 1998. *Guidelines for the Management of Adverse Drug Effects of Antimycobacterial Agents*. Philadelphia Tuberculosis Control Program.
- Li, J., Yang, G., Cai, Q., Wang, Y., Xu, Y., Zhang, R., dkk., 2021. Safety, efficacy, and serum concentration monitoring of bedaquiline in Chinese patients with multidrug-resistant tuberculosis. *International Journal of Infectious Diseases*, **110**: 179–186.
- Li, M. dan Ramos, L.G., 2017. Drug-Induced QT Prolongation And Torsades de Pointes. *Pharmacy and Therapeutics*, **42**: 473–477.
- Li, Y., Wang, F., Wu, L., Zhu, M., He, G., Chen, X., dkk., 2019. Cycloserine for treatment of multidrug-resistant tuberculosis: a retrospective cohort study in China. *Infection and Drug Resistance*, **Volume 12**: 721–731.
- Liu, Q., Lu, P., Martinez, L., Yang, H., Lu, W., Ding, X., dkk., 2018. *Factors affecting time to sputum culture conversion and treatment outcome of patients with multidrug-resistant tuberculosis in China*. *BMC Infectious Diseases*, **18**: 114.
- Lofranco, V.S., Jr, V.M.B., Raymond, L.O., Macalalad, N.G., Golubkov, A., Santiago, M.R.T., dkk., 2022a. Effectiveness and Safety of 9-Month Treatment Regimen for Multidrug-Resistant Tuberculosis in the Philippines. *Journal of Tuberculosis Research*, **10**: 75–86.

- Lofranco, V.S., Torres-Cervas, M.R.A., Asence, K.A., Del Mundo, K.M.A., Balanag, V.M., Santiago, M.R.T., dkk., 2022b. Interim Outcomes and Adverse Events among Drug-Resistant Tuberculosis Patients Treated with Bedaquiline in the Philippines. *Journal of Tuberculosis Research*, **10**: 61–74.
- Lv, L., Li, T., Xu, K., Shi, P., He, B., Kong, W., dkk., 2018. *Sputum bacteriology conversion and treatment outcome of patients with multidrug-resistant tuberculosis*. Infection and Drug Resistance, **11**: 147–154.
- Mafukidze, A.T., Calnan, M., dan Furin, J., 2016a. Peripheral neuropathy in persons with tuberculosis. *Journal of Clinical Tuberculosis and Other Mycobacterial Diseases*, **2**: 5–11.
- Mafukidze, A.T., Calnan, M., dan Furin, J., 2016b. Peripheral neuropathy in persons with tuberculosis. *Journal of Clinical Tuberculosis and Other Mycobacterial Diseases*, **2**: 5–11.
- Management Sciences for Health and World Health Organization, 2007. *Drug and Therapeutics Committee Training Course*. Management Sciences for Health, Geneva.
- Mantefardo, B. dan Sisay, G., 2021a. Case Report: Kanamycin Ototoxicity and MDR-TB Treatment Regimen. *International Medical Case Reports Journal*, **Volume 14**: 815–817.
- Mantefardo, B. dan Sisay, G., 2021b. Case Report: Kanamycin Ototoxicity and MDR-TB Treatment Regimen. *International Medical Case Reports Journal*, **14**: 3.
- Mase, S., Chorba, T., Parks, S., Belanger, A., Dworkin, F., Seaworth, B., dkk., 2020a. Bedaquiline for the Treatment of Multidrug-resistant Tuberculosis in the United States. *Clinical Infectious Diseases: An Official Publication of the Infectious Diseases Society of America*, **71**: 1010–1016.
- Mase, S., Chorba, T., Parks, S., Belanger, A., Dworkin, F., Seaworth, B., dkk., 2020b. Bedaquiline for the Treatment of Multidrug-resistant Tuberculosis in the United States. *Clinical Infectious Diseases*, **71**: 1010–1016.
- Mbuagbaw, L., Guglielmetti, L., Hewison, C., Bakare, N., Bastard, M., Caumes, E., dkk., 2019. Outcomes of Bedaquiline Treatment in Patients with Multidrug-Resistant Tuberculosis. *Emerging Infectious Diseases*, **25**: 11.
- McGee, E.U., Samuel, E., Boronea, B., Dillard, N., Milby, M.N., dan Lewis, S.J., 2019. Quinolone Allergy. *Pharmacy: Journal of Pharmacy Education and Practice*, **7**: 97.
- Menon, S., Dharmshale, S., Chande, C., Gohil, A., Lilani, S., Mohammad, S., dkk., 2012. Drug resistance profiles of Mycobacterium tuberculosis isolates to first line anti-tuberculous drugs: A five years study. *Lung India : Official Organ of Indian Chest Society*, **29**: 227–231.
- Minardi, M.L., Fato, I., Di Gennaro, F., Mosti, S., Mastrobattista, A., Cerva, C., dkk., 2021. Common and Rare Hematological Manifestations and Adverse Drug Events during Treatment of Active TB: A State of Art. *Microorganisms*, **9**: 1477.
- Molla, Y., Wubetu, M., dan Dessie, B., 2021. Anti-Tuberculosis Drug Induced Hepatotoxicity and Associated Factors among Tuberculosis Patients at

- Selected Hospitals, Ethiopia. *Hepatic Medicine: Evidence and Research*, **13**: 1–8.
- Muhammad, N., Mehboob, S., dan Abbas, M., 2021. Pyrazinamide Induced Hyperuricemia in the Induction Phase of Anti-Tuberculosis Therapy. *Pakistan Journal of Medical and Health Sciences*, **15**: 1136–1138.
- Munivenkatappa, S., Anil, S., Naik, B., Volkmann, T., Sagili, K.D., Akshatha, J.S., dkk., 2016. Drug-Induced Hypothyroidism during Anti-Tuberculosis Treatment of Multidrug-Resistant Tuberculosis: Notes from the Field. *Journal of Tuberculosis Research*, **04**: 105–110.
- Nasiri, M.J., Imani Fooladi, A.A., Dabiri, H., Pormohammad, A., Salimi Chirani, A., Dadashi, M., dkk., 2016. Primary ethambutol resistance among Iranian pulmonary tuberculosis patients: a systematic review. *Therapeutic Advances in Infectious Disease*, **3**: 133–138.
- Nugroho, N.P. dan Kusmiati, T., 2021. Allergic Reaction due to Anti-Tuberculosis Drugs, How to Manage? *Jurnal Respirasi*, **7**: 79.
- Oehadian, A., Santoso, P., Menzies, D., dan Ruslami, R., 2022. Anemia with elevation of growth differentiation factor-15 level in linezolid treated multidrug-resistant tuberculosis: Case series of three patients. *IDCases*, **29**: e01591.
- Oh, Y.R., Carr-Lopez, S.M., Probasco, J.M., dan Crawley, P.G., 2003. Levofloxacin-induced autoimmune hemolytic anemia. *The Annals of Pharmacotherapy*, **37**: 1010–1013.
- Palomino, J.C. dan Martin, A., 2013. TMC207 becomes bedaquiline, a new anti-TB drug. *Future Microbiology*, **8**: 1071–1080.
- Parmar, M.M., Sachdeva, K.S., Dewan, P.K., Rade, K., Nair, S.A., Pant, R., dkk., 2018. Unacceptable treatment outcomes and associated factors among India's initial cohorts of multidrug-resistant tuberculosis (MDR-TB) patients under the revised national TB control programme (2007–2011): Evidence leading to policy enhancement. *PLOS ONE*, **13**: e0193903.
- Pham, Antony Q., Doan, A., dan Andersen, M., 2014. Pyrazinamide-Induced Hyperuricemia. *Pharmacy and Therapeutics*, **39**: 695–715.
- Pham, Antony Q., Doan, A., dan Andersen, M., 2014. Pyrazinamide-Induced Hyperuricemia. *Pharmacovigilance Forum*, **39**: 4.
- Pichholiya, M., Yadav, A.K., Luhadia, S.K., Tahashildar, J., dan Aseri, M.L., 2016. A comparative study of efficacy and safety of febuxostat and allopurinol in pyrazinamide-induced hyperuricemic tubercular patients. *Indian Journal of Pharmacology*, **48**: 522–525.
- Pizzol, D., Veronese, N., Marotta, C., Di Gennaro, F., Moiane, J., Chhaganlal, K., dkk., 2018. Predictors of therapy failure in newly diagnosed pulmonary tuberculosis cases in Beira, Mozambique. *BMC Research Notes*, **11**: .
- Polprasert, C. dan Prayongratana, K., 2009. Levofloxacin-induced severe thrombocytopenia. *Journal of the Medical Association of Thailand = Chotmaihet Thangphaet*, **92 Suppl 3**: S69-71.
- Pradipta, I., 2020. 'Improving treatment outcomes of tuberculosis: towards an antimicrobial stewardship program', . University of Groningen.

- Pratama, N.Y.I., Zulkarnain, B.S., Soedarsono, null, dan Fatmawati, U., 2021a. Hematological side effect analysis of linezolid in MDR-TB patients with individual therapy. *Journal of Basic and Clinical Physiology and Pharmacology*, **32**: 777–781.
- Pratama, N.Y.I., Zulkarnain, B.S., Soedarsono, dan Fatmawati, U., 2021b. Hematological side effect analysis of linezolid in MDR-TB patients with individual therapy. *Journal of Basic and Clinical Physiology and Pharmacology*, **32**: 777–781.
- Primadana, V., Yovi, I., dan Estiningsih, D.S., 2022. Bedaquiline Correlation to QT Interval Prolongation in DR-TB Patients. *Jurnal Respirasi*, **08**: 7.
- Putra, I.W.A., Lonovi, K., Damayanti, L., dan Kamajaya, T., 2021. 'Characteristic of SGOT and SGPT Elevation in Patient with Lung Tuberculosis within OAT Therapy:: From Lung Policlinic RSUP Dr. Hasan Sadikin Bandung within 2016', . Dipresentasikan pada 12th Annual Scientific Meeting, Medical Faculty, Universitas Jenderal Achmad Yani, International Symposium on “Emergency Preparedness and Disaster Response during COVID 19 Pandemic” (ASMC 2021)), Bandung, Indonesia.
- Putra, O.N., N.h, A.Y., Hidayat, F., dan Sagitha, I.G.E., 2022. Ototoxicity in Multidrug-Resistant Tuberculosis: A Scoping Review of the Indonesian Studies. *Journal of Pharmaceutical And Sciences*, **5**: 62–73.
- Rahman, A.O. dan Thobari, J.A., 2012. Association of hydrazine and SGPT level two hours after drug administration at the end of intensive phase treatment of pulmonary tuberculosis patients. *Tropical Medicine Journal*, **02**: 10.
- Ramappa, V. dan Aithal, G.P., 2013. Hepatotoxicity Related to Anti-tuberculosis Drugs: Mechanisms and Management. *Journal of Clinical and Experimental Hepatology*, **3**: 37–49.
- Reis-Santos, B., Gomes, T., Horta, B.L., dan Maciel, E.L.N., 2013. The outcome of tuberculosis treatment in subjects with chronic kidney disease in Brazil: a multinomial analysis. *Jornal Brasileiro de Pneumologia*, **39**: 585–594.
- Rich, M.L., Seung, K.J., Tavares, A.C., Barrera-Cancedda, A.E., dan Tierney, D., 2013. *The PIH Guide to the Medical Management of Multidrug-Resistant Tuberculosis*, 2nd ed. Partners In Health, Boston, USA.
- Rifat, M., Hall, J., Oldmeadow, C., Husain, A., Hinderaker, S.G., dan Milton, A.H., 2015. Factors related to previous tuberculosis treatment of patients with multidrug-resistant tuberculosis in Bangladesh. *BMJ Open*, **5**: e008273.
- Rumende, C.M., 2018. Diagnosis dan Tatalaksana Tuberkulosis Resistan Obat 9.
- Sandhu, P. dan Akhter, Y., 2018. Evolution of structural fitness and multifunctional aspects of mycobacterial RND family transporters. *Archives of Microbiology*, **200**: 19–31.
- Saraf, G., Akshata, J.S., Kuruthukulangara, S., Thippeswamy, H., Reddy, S.K., Buggi, S., dkk., 2015. Cycloserine induced delirium during treatment of multi-drug resistant tuberculosis (MDR-TB). *Egyptian Journal of Chest Diseases and Tuberculosis*, **64**: 449–451.
- Sari, T.N., Retnowulan, H., Hisyam, B., Riyanto, B.S., Budiono, E., dan Trisnawati, I., 2016. Interaction of Side Effects of Second Line TB Drugs

- Therapy in MDR-TB: Ethionamide- induced Hypothyroid and Cycloserine-induced Depression Episode. *Indonesian Journal of Critical and Emergency Medicine*, **3**: 5.
- Sasongko, D. dan Hasan, H., 2020. Factors Affecting Uric Acid Changes in Pulmonary Tuberculosis Patients Who Received Oral Anti Tuberculosis Therapy During One Month. *Medico-Legal Update*, **20**: 836–842.
- Satti, H., Mafukidze, A., Jooste, P.L., McLaughlin, M.M., Farmer, P.E., dan Seung, K.J., 2012. High rate of hypothyroidism among patients treated for multidrug-resistant tuberculosis in Lesotho. *The International Journal of Tuberculosis and Lung Disease: The Official Journal of the International Union Against Tuberculosis and Lung Disease*, **16**: 468–472.
- Saxena, R., Singh, D., Phuljhele, S., Kalaiselvan, V., Karna, S., Gandhi, R., dkk., 2021. Ethambutol toxicity: Expert panel consensus for the primary prevention, diagnosis and management of ethambutol-induced optic neuropathy. *Indian Journal of Ophthalmology*, **69**: 3734–3739.
- Sayamber, A., 2017. A study of changes in SGPT and SGOT over time the patients of drug induced hepatitis taking antitubercular drugs **3**: 7.
- Scardigli, A., Caminero, J.A., Sotgiu, G., Centis, R., D'Ambrosio, L., dan Migliori, G.B., 2016. Efficacy and tolerability of ethionamide versus prothionamide: a systematic review. *European Respiratory Journal*, **48**: 946–952.
- Schnippel, K., Ndjeka, N., Maartens, G., Meintjes, G., Master, I., Ismail, N., dkk., 2018. Effect of bedaquiline on mortality in South African patients with drug-resistant tuberculosis: a retrospective cohort study. *The Lancet Respiratory Medicine*, **6**: 699–706.
- Seaworth, B. dan Griffith, D.E., 2016. Adverse reactions and toxicity should be anticipated with any treatment course for drug-resistant TB., dalam: *Drug-Resistant Tuberculosis: A Survival Guide for Clinicians*. Curry International Tuberculosis Center, San Francisco, hal. 32.
- Seung, K.J., Keshavjee, S., dan Rich, M.L., 2015. Multidrug-Resistant Tuberculosis and Extensively Drug-Resistant Tuberculosis. *Cold Spring Harbor Perspectives in Medicine*, **5**: a017863.
- Shang, P., Xia, Y., Liu, F., Wang, X., Yuan, Y., Hu, D., dkk., 2011. Incidence, Clinical Features and Impact on Anti-Tuberculosis Treatment of Anti-Tuberculosis Drug Induced Liver Injury (ATLI) in China. *PLOS ONE*, **6**: e21836.
- Sharma, B., Handa, R., Nagpal, K., Prakash, S., Gupta, P.K., dan Agrawal, R., 2014. Cycloserine-induced psychosis in a young female with drug-resistant tuberculosis. *General Hospital Psychiatry*, **36**: 451.e3–4.
- Sharma, S., 2014. *Nursing Research & Statistics*, Second Edition. ed. Elsevier Health Sciences APAC, London.
- Sheikh-Taha, M. dan Frenn, P., 2014. Autoimmune Hemolytic Anemia Induced by Levofloxacin. *Case Reports in Infectious Diseases*, **2014**: 201015.
- Shibeshi, W., Sheth, A.N., Admasu, A., Berha, A.B., Negash, Z., dan Yimer, G., 2019. Nephrotoxicity and ototoxic symptoms of injectable second-line

- anti-tubercular drugs among patients treated for MDR-TB in Ethiopia: a retrospective cohort study. *BMC Pharmacology and Toxicology*, **20**: 31.
- Shin, S., Furin, J., Alcántara, F., Hyson, A., Joseph, K., Sánchez, E., dkk., 2004a. Hypokalemia Among Patients Receiving Treatment for Multidrug-Resistant Tuberculosis. *CHEST*, **125**: 974–980.
- Shin, S., Furin, J., Alcántara, F., Hyson, A., Joseph, K., Sánchez, E., dkk., 2004b. Hypokalemia Among Patients Receiving Treatment for Multidrug-Resistant Tuberculosis. *Chest*, **125**: 974–980.
- Shinnick, T.M., Starks, A.M., Alexander, H.L., dan Castro, K.G., 2015. Evaluation of the Cepheid Xpert MTB/RIF assay. *Expert review of molecular diagnostics*, **15**: 9–22.
- Soedarsono, S. dan Riadi, A.R.W., 2020. Tuberculosis Drug-Induced Liver Injury. *Jurnal Respirasi*, **6**: 49.
- Soeroto, A.Y., Darmawan, G., Supriyadi, R., Bhaskara, P.G., Santoso, P., Alisjahbana, B., dkk., 2019. Comparison of Serum Potassium, Magnesium, and Calcium Levels between Kanamycin and Capreomycin-BASEd Regimen-Treated MultiDrug-Resistant Tuberculosis Patients in Bandung (CEASE MDR-TB): A Retrospective Cohort Study. *International Journal of Microbiology*, **2019**: 1–7.
- Soeroto, A.Y., Pratiwi, C., Santoso, P., dan Lestari, B.W., 2021. Factors affecting outcome of longer regimen multidrug-resistant tuberculosis treatment in West Java Indonesia: A retrospective cohort study. *PLOS ONE*, **16**: e0246284.
- Stettner, M., Steinberger, D., Hartmann, C.J., Pabst, T., Konta, L., Hartung, H.P., dkk., 2015. Isoniazid-induced polyneuropathy in a tuberculosis patient - implication for individual risk stratification with genotyping? *Brain and Behavior*, **5**: n/a-n/a.
- Sultana, Z.Z., Hoque, F.U., Beyene, J., Akhlak-Ul-Islam, Md., Khan, M.H.R., Ahmed, S., dkk., 2021. HIV infection and multidrug resistant tuberculosis: a systematic review and meta-analysis. *BMC Infectious Diseases*, **21**: 51.
- Suparyatmo, J.B., Rina, B., Harsini, dan Sukma, 2014. Kalium di Multidrug Resistance Tuberkulosis dengan Pengobatan Kanamisin. *Indonesian Journal of Clinical Pathology and Medical Laboratory*, **21**: 16–19.
- Teng, C., Walter, E.A., Gaspar, D.K.S., Obodozie-Ofoegbu, O.O., dan Frei, C.R., 2019. Torsades de pointes and QT prolongation Associations with Antibiotics: A Pharmacovigilance Study of the FDA Adverse Event Reporting System. *International Journal of Medical Sciences*, **16**: 1018–1022.
- Theron, G., Venter, R., Smith, L., Esmail, A., Randall, P., Sood, V., dkk., 2018. False-Positive Xpert MTB/RIF Results in Retested Patients with Previous Tuberculosis: Frequency, Profile, and Prospective Clinical Outcomes. *Journal of Clinical Microbiology*, **56**: e01696-17.
- Thumamo Pokam, B., Enoh, J., Eyo, A.-A., Umoh, N., dan Guemdjom, P., 2018. Uric acid levels in patients on antituberculosis drugs in the southwest Region of Cameroon. *International Journal of Mycobacteriology*, **7**: 89.

- Tiwari, M., Patel, M., dan Shamaliya, K., 2015. Peripheral neuropathy in XDR-TB patients on second line anti-tubercular therapy. *European Respiratory Journal*, **46**: .
- Tola, H.H., Holakouie-Naieni, K., Lejisa, T., Mansournia, M.A., Yaseri, M., Tesfaye, E., dkk., 2019. Is hypothyroidism rare in multidrug resistance tuberculosis patients on treatment? A systematic review and meta-analysis. *PLOS ONE*, **14**: e0218487.
- Tornheim, J.A., Udwadia, Z.F., Arora, P.R., Gajjar, I., Gupte, N., Sharma, S., dkk., 2022. Cycloserine did not increase depression incidence or severity at standard dosing for multidrug-resistant tuberculosis. *European Respiratory Journal*, **59**: 2102511.
- Tupasi, T.E., Garfin, A.M.C.G., Kurbatova, E.V., Mangan, J.M., Orillaza-Chi, R., Naval, L.C., dkk., 2016. Factors Associated with Loss to Follow-up during Treatment for Multidrug-Resistant Tuberculosis, the Philippines, 2012–2014. *Emerging Infectious Diseases*, **22**: 491–502.
- Vishnu, V.Y., Modi, M., Goyal, M.K., dan Lal, V., 2016. Linezolid Induced Reversible Peripheral Neuropathy. *American Journal of Therapeutics*, **23**: e1839–e1841.
- Wallis, R.S., 2016. Cardiac safety of extensively drug-resistant tuberculosis regimens including bedaquiline, delamanid and clofazimine. *European Respiratory Journal*, **48**: 1526–1527.
- Wang, C.S., Yang, C.J., Chen, H.C., Chuang, S.H., Chong, I.W., Hwang, J.J., dkk., 2009. Impact of type 2 diabetes on manifestations and treatment outcome of pulmonary tuberculosis. *Epidemiology and Infection*, **137**: 203–210.
- Wen, Y., Zhang, Z., Li, X., Xia, D., Ma, J., Dong, Y., dkk., 2018. Treatment outcomes and factors affecting unsuccessful outcome among new pulmonary smear positive and negative tuberculosis patients in Anqing, China: a retrospective study. *BMC Infectious Diseases*, **18**: 104.
- WHO, 2009. *Management of MDR-TB: A Field Guide: A Companion Document to Guidelines for Programmatic Management of Drug-Resistant Tuberculosis: Integrated Management of Adolescent and Adult Illness (IMAI)*. Management of MDR-TB: A Field Guide: A Companion Document to Guidelines for Programmatic Management of Drug-Resistant Tuberculosis: Integrated Management of Adolescent and Adult Illness (IMAI). World Health Organization.
- WHO, 2013. 'The Use of the WHO-UMC System For Standardised Case Causality Assessment', .
- WHO, W.H.O., 2010. *Treatment of Tuberculosis: Guidelines*, 4th ed. World Health Organization, Geneva, Switzerland.
- WHO, [World Health Organization], 2015. *Introduction of Bedaquiline for the Treatment of Multidrug-Resistant Tuberculosis at Country Level*. WHO press, Geneva, Switzerland.
- Widyasrini, E.R., Masters Program in Family Medicine, Sebelas Maret University, Probandari, A.N., Faculty of Medicine, Sebelas Maret University, -, R., dan Department of Pulmonology and Respiratory

- Medicine, Dr. Moewardi, Surakarta, 2017. Factors Affecting the Success of Multi Drug Resistance (MDR-TB) Tuberculosis Treatment in Residential Surakarta. *Journal of Epidemiology and Public Health*, **02**: 45–57.
- World Health Organization, 2013. *The Use of Bedaquiline in the Treatment of Multidrug-Resistant Tuberculosis: Interim Policy Guidance*. World Health Organization, Geneva.
- World Health Organization, 2014. *Companion Handbook to the WHO Guidelines for the Programmatic Management of Drug-Resistant Tuberculosis*. World Health Organization, Geneva.
- World Health Organization, 2015. *Introduction of Bedaquiline for the Treatment of Multidrug-Resistant Tuberculosis at Country Level*. World Health Organization, Geneva.
- World Health Organization, 2020a. 'Global Tuberculosis Report 2020', . World Health Organization, Geneva.
- World Health Organization, 2020b. 'Tuberculosis (TB)', . URL: <https://www.who.int/news-room/fact-sheets/detail/tuberculosis> (diakses tanggal 18/9/2021).
- World Health Organization, 2020c. *WHO Consolidated Guidelines on Tuberculosis, Module 4: Treatment - Drug-Resistant Tuberculosis Treatment*. WHO, Geneva.
- Wulandari, I.S.M., Rantung, J., dan Malinti, E., 2020. Faktor yang Berhubungan dengan Kepatuhan Minum Obat Pasien TBC di Wilayah Kerja Puskesmas Parongpong. *Jurnal Keperawatan Muhammadiyah*, **5**: .
- Yang, T.W., Park, H.O., Jang, H.N., Yang, J.H., Kim, S.H., Moon, S.H., dkk., 2017a. Side effects associated with the treatment of multidrug-resistant tuberculosis at a tuberculosis referral hospital in South Korea: A retrospective study. *Medicine*, **96**: e7482.
- Yang, T.W., Park, H.O., Jang, H.N., Yang, J.H., Kim, S.H., Moon, S.H., dkk., 2017b. Side effects associated with the treatment of multidrug-resistant tuberculosis at a tuberculosis referral hospital in South Korea: A retrospective study. *Medicine*, **96**: e7482.
- Yu, M.-C., Chiang, C.-Y., Lee, J.-J., Chien, S.-T., Lin, C.-J., Lee, S.-W., dkk., 2018. Treatment Outcomes of Multidrug-Resistant Tuberculosis in Taiwan: Tackling Loss to Follow-up. *Clinical Infectious Diseases*, **67**: 202–210.
- Zhurkin, D., Gupta, R.K., Gadoev, J., Dadu, A., Davtyan, K., Hurevich, H., dkk., 2019. Effectiveness and safety of bedaquiline-containing regimens among adults with multidrug- or extensively drug-resistant pulmonary TB in Belarus: a nationwide cohort study **5**: 9.